408-854-1883 starts at $30 per hr home care

  • Caregivers
  • Senior
  • Blogs
  • About Us
  • Contact Us
  • Caregivers
  • Senior
  • Blogs
  • About Us
  • Contact Us

Marketplace

Soon

408-854-1883 text

Marketplace

Soon

Book an Appointment

Affordable in home care | starts at $28 per hr

Beware of blue light from your cell phone

Shorter wavelength blue light that is emitted by smartphones, lights, and computer, tablet, and TV screens causes damaging health effects. Exposure to this wavelength of light disrupts circadian rhythms. Exposure to blue light after the sun goes down interferes with sleep. Blue light may contribute to heart disease, obesity, diabetes, and other health conditions. Minimize your exposure to unnecessary light, including smartphone screens, after dark. You will also sleep better if you get a lot of exposure to natural light during the day.


Do not text while driving and avoid talking with your cell while driving. Get a head set.

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuLeave a comment on Beware of blue light from your cell phone

Fact sheet about exercise and supplements

exercise supp 4exercise supp 3exercise supp 2exercise supp 1

After exercising, I nourish my body with whole foods and supplementation. Eggs, beets, carrots, cooked tomatoes, fish , turmeric, ginger and other whole foods.

https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-Consumer/

When busy, I need to nourish my body from greens and protein powder I get from Pharmanex at http://www.nuskin.com . Check the menu in this site for the sponsor ID to get discount as distributor, join for free.

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:exercise, supplementsLeave a comment on Fact sheet about exercise and supplements

Study links gut-homing protein levels with HIV infection risk, disease progression

Study links gut-homing protein levels with HIV infection risk, disease progression

NIH clinical trial is testing antibody against the protein in people with HIV.

Healthy Human T CellScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. NIAID

For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes. Previous research illustrated this relationship in monkeys infected with a simian form of HIV.

The new study found that women who had more CD4+ T cells displaying high levels of alpha-4 beta-7 on their surface were more likely to become infected with HIV, and the virus damaged their immune systems more rapidly, than women with fewer such cells. The National Institutes of Health co-funded the study with the South African Medical Research Council as part of the U.S.–South Africa Program for Collaborative Biomedical Research. In addition, NIH scientists collaborated on the study. The report appears online today in the journal Science Translational Medicine.

“Our findings suggest that having a high frequency of alpha-4 beta-7-expressing CD4+ T cells, which HIV preferentially infects, leads to more HIV-infected CD4+ T cells moving to the gut, which in turn leads to extensive damage to gut-based immune cells,” said Anthony S. Fauci, M.D. Dr. Fauci co-authored the paper as chief of the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. He also is director of NIAID.

The study was led by Lyle McKinnon, Ph.D., and Aida Sivro, Ph.D., both researchers at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in Durban, South Africa. Dr. McKinnon is also an assistant professor in the Rady Faculty of Health Sciences at the University of Manitoba in Winnipeg, Canada, and an honorary lecturer at the University of Nairobi in Kenya.

The research team compared the percentage of CD4+ T cells displaying high levels of alpha-4 beta-7 in blood samples drawn from 59 women shortly before they acquired HIV to the percentage of such cells in 106 women who remained HIV negative. Aged 18 to 40 years, the women were selected from participants in the CAPRISA 004 study(link is external), which evaluated the safety and efficacy of tenofovir gel for HIV prevention in KwaZulu-Natal, South Africa, from 2007 to 2010. Understanding HIV acquisition and disease progression among African women is especially important because women accounted for nearly 60 percent of new HIV infections among adults in sub-Saharan Africa in 2016.

The proportion of CD4+ T cells with high levels of alpha-4 beta-7 had an effect, albeit modest, on the risk of acquiring HIV among both the women in the CAPRISA 004 study and a separate cohort of 41 female sex workers in Kenya. The risk of HIV acquisition rose by 18 percent for each one percent increase in alpha-4 beta-7 protein. The authors show a similar association in monkeys that were vaginally exposed to a simian form of HIV.

The proportion of CD4+ T cells with high levels of alpha-4 beta-7 strongly affected how quickly HIV damaged the immune system. CD4+ T cell levels declined twice as fast among women with higher pre-infection levels of alpha-4 beta-7 as among women with lower pre-infection levels. In addition, the amount of HIV in the blood within a few months of infection was greater in women with higher pre-infection levels of alpha-4 beta-7 than in women with lower pre-infection levels. The mechanism for the immune system damage likely was HIV-related damage to the gut, the scientists report, as higher pre-infection levels of alpha-4 beta-7 were associated with higher levels of a biological marker of gut damage.

The scientists found that HIV targets CD4+ T cells displaying alpha-4 beta-7 very early in infection, particularly in the gut. In this regard, the researchers looked at data from the U.S. Military HIV Research Program-led RV254 clinical trial at the Thai Red Cross in Bangkok, Thailand, and found that starting antiretroviral therapy (ART) right after HIV diagnosis did not prevent the depletion of CD4+ T cells from the gut or facilitate reconstitution of the depleted cells.

“These findings suggest that interventions in addition to ART may be needed to restore CD4+ T cells in the GI tracts of people living with HIV,” said Dr. McKinnon. “One such intervention could be an anti-alpha-4 beta-7 antibody called vedolizumab, which is FDA-approved for the treatment of ulcerative colitis and Crohn’s disease.”

In previous studies led by Dr. Fauci and Aftab A. Ansari, Ph.D., of Emory University in Atlanta, a monkey-adapted form of vedolizumab contributed to the near-replenishment in monkeys of CD4+ T cells that had been destroyed by a simian form of HIV. Based on this and related findings, NIAID initiated an early-phase clinical trial in 2017 to determine whether short-term treatment with vedolizumab in combination with ART could generate sustained HIV remission in people living with HIV. The study is taking place at the NIH Clinical Research Center in Bethesda, Maryland. Preliminary results are expected later this year. More information about the study is available at ClinicalTrials.gov under study identifier NCT02788175.

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

Reference

A Sivro et al. Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. Science Translational Medicine DOI: 10.1126/scitranslmed.aam6354 (2018).

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:cell adhesion, endothelial cells, gut, HIV, immune system, infection, lymphocytes, womenLeave a comment on Study links gut-homing protein levels with HIV infection risk, disease progression

Love and the μ-Opioid Receptor

  • TWIS

    Orphan opioid | Science

    NOV. 2, 1995

    Orphan opioid. Science 03 Nov 1995: Vol. 270, Issue 5237, pp. 713. DOI: 10.1126/science.270.5237.713f. Article · Info & Metrics · eLetters. Loading. Science: 270 (5237) …

    • science.sciencemag.org/content/270/5237/713.6

    DOI: 10.1126/science.270.5237.713f

  • Painful marks of childhood abuse …

    Although studies indicate that the opioid system controls mood-related processes and social behaviors, whether and how stressful childhood experiences impact the opioid system to increase risk for psychopathology and suicide remain unknown. Because epigenetic factors, including DNA methylation, are implicated as the …

    • stm.sciencemag.org/content/9/403/eaao4207.full.txt
  • Cannabinoid and Heroin Activation of Mesolimbic Dopamine …

    Opioid Receptor Mechanism. Gianluigi Tanda, Francesco E. Pontieri,* Gaetano Di Chiara†. The effects of the active ingredient of Cannabis, 9-tetrahydrocannabinol (9-THC), and of the highly addictive drug heroin on in vivo dopamine transmission in the nucleus accumbens were compared in Sprague-Dawley rats by brain …

    • science.sciencemag.org/content/sci/276/5321/2048.full.pdf
  • REPORT

    COMT val158met Genotype Affects µ-Opioid Neurotransmitter …

    FEB. 20, 2003

    Individuals homozygous for themet158 allele of the catechol-O-methyltransferase (COMT) polymorphism (val158met) showed diminished regional μ-opioid system responses to pain compared with heterozygotes. These effects were accompanied by higher sensory and affective ratings of pain and a more negative internal …

    • science.sciencemag.org/user/logout?current=node/386932

    DOI: 10.1126/science.1078546

  • REPORT

    5-HT4(a) Receptors Avert Opioid-Induced Breathing Depression …

    JUL. 10, 2003

    Treatment of rats with a 5-HT4 receptor–specific agonist overcame fentanyl-induced respiratory depression and reestablished stable respiratory rhythm without loss of fentanyl’s analgesic effect. These findings imply the prospect of a fine-tuned recovery from opioid-induced respiratory depression, through adjustment of …

    • science.sciencemag.org/content/301/5630/226

    DOI: 10.1126/science.1084674

  • EDITORS’ CHOICE

    Opioid-Related Peptides for Treating Anxiety | Science Signaling

    BY NANCY R. GOUGH | DEC. 16, 2013

    The transcript for proenkephalin A, which can be cleaved to produce various bioactive peptides, including those acting on opioid receptors, and various proenkephalin A–derived peptide fragments were abundant in SCH cells. Secretion of the stress-responsive hormone glucocorticoid is circadian, and female, but not male, …

    • stke.sciencemag.org/content/6/306/ec308

    DOI: 10.1126/scisignal.2005005

  • NEWS OF THE WEEK

    The Mice That Don’t Miss Mom: Love and the μ-Opioid Receptor …

    BY MARY BECKMAN | JUN. 24, 2004

    The Mice That Don’t Miss Mom: Love and the μ-Opioid Receptor. Mary Beckman*. Mary Beckman is a writer based in southeastern Idaho. See allHide authors and affiliations. Science 25 Jun 2004: Vol. 304, Issue 5679, pp. 1888-1889. DOI: 10.1126/science.304.5679.1888a. Mary Beckman. Mary Beckman is a writer based …

    • science.sciencemag.org/content/304/5679/1888.1

    DOI: 10.1126/science.304.5679.1888a

  • REPORTS

    Opioid peptides modulate luteinizing hormone secretion during …

    BY MS BLANK | MAR. 15, 1979

    Abstract. Subcutaneous injections of naloxone, an opiate antagonist, lead to an increase in serum luteinizing hormone concentrations in female but not in male rats before they reach puberty. In addition, estradiol benzoate specifically blocks the luteinizing hormone response to naloxone in prepubertal female rats, …

    • science.sciencemag.org/content/203/4385/1129

    DOI: 10.1126/science.424743

  • Figure 2 | Broad-Spectrum, Non-Opioid Analgesic Activity by …

    Figure 2. (A), (C), and (E) show the effects of ABT-594 (squares), (−)−nicotine (circles), and morphine (triangles) in preclinical models of acute, persistent, and neuropathic pain. All compounds were administered ip. Each compound was tested independently, but for graphical presentation, control (that is, saline-treated …

    • science.sciencemag.org/content/279/5347/77/F2
  • RESEARCH NEWS

    Synthesizing the opioid peptides | Science

    BY JL MARX | APR. 21, 1983

    Synthesizing the opioid peptides. See allHide authors and affiliations. Science 22 Apr 1983: Vol. 220, Issue 4595, pp. 395-397. DOI: 10.1126/science.6836282. JL Marx. Find this author on Google Scholar · Find this author on PubMed · Search for this author on this site · Article; Info & Metrics; eLetters; PDF. Loading.

    • science.sciencemag.org/content/220/4595/395

    DOI: 10.1126/science.6836282

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:love, opioidsLeave a comment on Love and the μ-Opioid Receptor

Opioid receptor was present in the nerves associated with the portal vein that collects blood from the gut

  • Opioid Receptor Satiety Signal | Science Signaling

    BY NANCY R. GOUGH | JUL. 23, 2012

    The sensations of hunger and satiety are mediated through communication between the gastrointestinal system and the brain. Duraffourd et al. found that μ-opioid receptor (MOR)–1 was present in the nerves associated with the portal vein that collects blood from the gut. Peptide products of protein digestion can function …

    • stke.sciencemag.org/content/5/234/ec195

    DOI: 10.1126/scisignal.2003416

  • Synthesizing the Opioid Peptides

    Synthesizing the Opioid Peptides. The opioid peptides are synthesized as parts of large precursor molecules that may be split to yield different products in different cells. The biosynthesis of the opioid pep- tides illustrates what seemsto be a gen- eral trend in neurobiology. Likemany other peptides that act in the nervous.

    • science.sciencemag.org/content/sci/220/4595/395.full.pdf
  • SCIENCEINSIDER

    Drug, HIV crises hit HHS nominee Price close to home | Science …

    BY MEREDITH WADMAN | DEC. 2, 2016

    Dec 2, 2016 … But Price’s district is also experiencing some public health crises that he will likely be dealing with as HHS secretary: a serious heroin and opioid abuse epidemic, as well as elevated HIV infection rates. The heroin problem was described in great detail in this investigative special by the local NBC affiliate …

    • http://www.sciencemag.org/…/drug-hiv-crises-hit-hhs-nominee-price-close-home
  • REPORT

    COMT val158met Genotype Affects µ-Opioid Neurotransmitter …

    FEB. 20, 2003

    We detected significant effects of genotype on μ-opioid system activation (degrees of freedom = 2, 15 for all regions,P < 0.05 after correction for multiple comparisons) in the anterior thalamus [x, y, zcoordinates (millimeters), 5, −1, −2; F = 29.3], the thalamic pulvinar ipsilateral to the painful challenge (x,y, z, −8, −24, 8; …

    • science.sciencemag.org/content/299/5610/1240.full

    DOI: 10.1126/science.1078546

  • Constitutive μ-Opioid Receptor Activity Leads to Long-Term …

    SEP. 19, 2013

    Pain and Dependence. The properties and functions of µ-opioid receptors have been studied intensively with respect to the binding of endogenous or exogenous ligands. However, much less is known about the constitutive, ligand-independent, activation of opioid receptors. Working in mice, Corder et al. (p. 1394) observed …

    • science.sciencemag.org/user/logout?current=node/494607
  • Even more pain in opioid treatment | Science

    BY L. BRYAN RAY | JUL. 7, 2016

    Jul 8, 2016 … Amid heightened concern about the addictive properties of opiates used to manage pain, new results from Grace et al. reveal that morphine can actually promote chronic pain. Rats with nerve damage treated for 5 days with morphine showed a sensitization to pain that persisted for months after opioid …

    • science.sciencemag.org/content/353/6295/134.3

    DOI: 10.1126/science.353.6295.134-c

  • REPORTS

    The opioid peptide dynorphin, circadian rhythms, and starvation …

    BY R PRZEWLOCKI | JAN. 6, 1983

    Abstract. Dynorphin, an opioid peptide whose functions are unknown, is found in brain, pituitary, and peripheral organs. Specific radioimmunoassays were used to measure dynorphin in the hypothalamus and pituitary, during the day and at night, as a function of food and water deprivation. Immunoreactive dynorphin was …

    • science.sciencemag.org/content/219/4580/71

    DOI: 10.1126/science.6129699

  • EDITORS’ CHOICE

    Regulating Opioid Responses | Science Signaling

    BY PETER R. STERN | OCT. 8, 2012

    Different drugs of abuse are thought to hijack similar reward systems in the brain using common mechanisms. However, Koo et al. now observe that some of the neural mechanisms that regulate opiate reward can be both different and even opposite to those that regulate reward by stimulant drugs. Whereas knockdown of …

    • stke.sciencemag.org/content/5/245/ec264?intcmp=trendmd-stke

    DOI: 10.1126/scisignal.2003665

  • REPORTS

    Opioid receptors undergo axonal flow | Science

    BY WS YOUNG | OCT. 2, 1980

    Abstract. Previous studies have indicated the presence of opiate receptors on axons of the rat vagus nerve and on other small diameter fibers. In examinations of the effect of ligation on the distribution of receptors in the vagus nerve by in vitro labeling light microscopic autoradiography, a large buildup of receptors was found …

    • science.sciencemag.org/content/210/4465/76

    DOI: 10.1126/science.6158097

  • REPORTS

    Opioid peptides may excite hippocampal pyramidal neurons by …

    BY W ZIEGLGANSBERGER | JUL. 26, 1979

    Abstract. The atypical excitation by opiates and opioid peptides of hippocampal pyramidal cells can be antagonized by iontophoresis of naloxone, the gamma-aminobutyric acid antagonists bicuculline, or magnesium ion. The recurrent inhibition of these cells evoked by transcallosal stimulation of the contralateral …

    • science.sciencemag.org/content/205/4404/415

    DOI: 10.1126/science.451610

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:blood, brain, hunger, nerves, opioids, Pain, signalsLeave a comment on Opioid receptor was present in the nerves associated with the portal vein that collects blood from the gut

Opioid addiction—degrades health, saps productivity, spawns crime, and devastates families

  • New painkillers could thwart opioids‘ fatal flaw

    BY MEREDITH WADMAN | NOV. 15, 2017

    Nov 16, 2017 … When people die from overdoses of opioids, whether prescription pain medications or street drugs, it is the suppression of breathing that almost always kills them. The drugs act on neuronal receptors to dull pain, but those in the brain stem also control breathing. When activated, they can signal respiration …

    • http://www.sciencemag.org/…/new-painkillers-could-thwart-opioids-fatal-flaw
  • SCIENCESHOTS

    Tropical fish fiend for opioids, too

    BY EMILY UNDERWOOD | AUG. 25, 2017

    Aug 25, 2017 … After just 5 days, the trained fish were visiting the opioid-delivering platform almost 2000 times every 50 minutes, the team reports online today in Behavioral Brain Research . When no drug was present, they visited the platform only about 200 times. Fish normally avoid shallow water, where they’re more …

    • http://www.sciencemag.org/news/2017/08/tropical-fish-fiend-opioids-too
  • Forecasting the opioid epidemic | Science

    BY DONALD S. BURKE | NOV. 3, 2016

    Nov 4, 2016 … Summary. Since 2000, almost half a million Americans have died from drug overdoses. This modern plague—largely driven by opioid addiction—degrades health, saps productivity, spawns crime, and devastates families, all at enormous societal cost. How did we get here, and what do we do now?

    • science.sciencemag.org/content/354/6312/529

    DOI: 10.1126/science.aal2943

  • SCIENCEINSIDER

    Expert panel to FDA: time to hold opioids to a new standard …

    BY KELLY SERVICK | JUL. 13, 2017

    Jul 13, 2017 … To help bolster its campaign against an epidemic of opioid abuse that now kills about 90 people a day, the U.S. Food and Drug Administration (FDA) last year called for help from an independent advisory panel. The resulting report, released today by the National Academies of Sciences, Engineering, and …

    • http://www.sciencemag.org/…/expert-panel-fda-time-hold-opioids-new-standard
  • Plasma membrane localization of the μ-opioid receptor controls …

    FEB. 8, 2016

    Spatiotemporal opioid receptor signaling. The μ-opioid receptor (MOR) is a GPCR that mediates the effects of endogenous opioids and opioid analgesics, such as morphine. Different MOR agonists produce different biological effects, in part by differentially regulating receptor phosphorylation and internalization. In cells …

    • stke.sciencemag.org/user/logout?current=node/207717
  • LATEST NEWS

    Could pot help solve the U.S. opioid epidemic?

    BY GREG MILLER | NOV. 2, 2016

    Nov 3, 2016 … Hints are emerging that cannabis could be an alternative to opioid painkillers.

    • http://www.sciencemag.org/…/could-pot-help-solve-us-opioid-epidemic
  • SCIENCEINSIDER

    Can social media help prevent opioid abuse?

    BY MAYA SMITH | JUL. 13, 2016

    Jul 13, 2016 … Can a social media strategy that has helped gay men combat HIV now help curb the abuse of powerful opioid drugs? That’s the question a team of researchers at the University of California, Los Angeles (UCLA), is asking in a pilot study highlighted by White House officials last week. The Harnessing Online …

    • http://www.sciencemag.org/…/can-social-media-help-prevent-opioid-abuse
  • Modeling the growth of opioid overdose deaths | Sciencehound

    JUN. 5, 2017

    Jun 5, 2017 … In his recent editorial Forecasting the opioid epidemic, Don Burke discussed the rise in opioid addiction in the United States and pointed to the need for data.

    • blogs.sciencemag.org/…/modeling-the-growth-of-opioid-overdose-deaths/
  • LATEST NEWS

    Why painkillers sometimes make the pain worse

    BY KELLY SERVICK | NOV. 2, 2016

    Nov 3, 2016 … Mark Hutchinson could read the anguish on the participants’ faces in seconds. As a graduate student at the University of Adelaide in Australia in the late 1990s, he helped with studies in which people taking methadone to treat opioid addiction tested their pain tolerance by dunking a forearm in ice water.

    • http://www.sciencemag.org/…/why-painkillers-sometimes-make-pain-worse
  • Quantitative Encoding of the Effect of a Partial Agonist on Individual …

    AUG. 8, 2011

    Here, we addressed this question by focusing on morphine, a partial agonist drug for μ-type opioid peptide receptors (MORs), and by combining quantitative mass spectrometry with cell biological analysis to investigate the reduced efficacy of morphine, compared to that of a peptide full agonist, in promoting receptor …

    • stke.sciencemag.org/user/logout?current=node/192398

     

    • Biased agonists of the kappa opioid receptor suppress pain and itch …

      NOV. 28, 2016

      Nov 29, 2016 … Itch relief from biased agonists. Activating the kappa opioid receptor (KOR) can relieve itching that is not caused by allergic reactions. However, compounds that activate this receptor also cause unwanted side effects, such as dysphoria and sedation. KOR activation can trigger multiple downstream …

      • stke.sciencemag.org/content/9/456/ra117
    • REPORT

      Complete biosynthesis of opioids in yeast | Science

      SEP. 3, 2015

      Toward opioids without poppy fields. Producing opioids without having to depend on field-grown poppies would be of great benefit. Synthetic production could potentially produce more-effective drugs with fewer side effects. Now, Galanie et al. have engineered yeast to produce the opioid compounds thebaine and …

      • science.sciencemag.org/content/349/6252/1095

      DOI: 10.1126/science.aac9373

    • REPORT

      Placebo and Opioid Analgesia– Imaging a Shared Neuronal Network

      BY PREDRAG PETROVIC | FEB. 28, 2002

      It has been suggested that placebo analgesia involves both higher order cognitive networks and endogenous opioid systems. The rostral anterior cingulate cortex (rACC) and the brainstem are implicated in opioidanalgesia, suggesting a similar role for these structures in placebo analgesia. Using positron emission …

      • science.sciencemag.org/content/295/5560/1737.full

      DOI: 10.1126/science.1067176

    • LATEST NEWS

      Why taking morphine, oxycodone can sometimes make pain worse …

      BY KELLY SERVICK | MAY 27, 2016

      May 30, 2016 … There’s an unfortunate irony for people who rely on morphine, oxycodone, and other opioid painkillers: The drug that’s supposed to offer you relief can actually make you more sensitive to pain over time. That effect, known as hyperalgesia, could render these medications gradually less effective for chronic …

      • http://www.sciencemag.org/…/why-taking-morphine-oxycodone-can-sometimes- make-pain-worse
    • RESEARCH ARTICLE

      Alcohol Consumption Induces Endogenous Opioid Release in the …

      JAN. 10, 2012

      Jan 11, 2012 … Studies in animals suggest that release of endogenous opioids by ethanol promotes further consumption. To examine this issue in humans and to determine where in the brain endogenous opioids act to promote alcohol consumption, we measured displacement of a radiolabeled μ opioid receptor agonist, …

      • stm.sciencemag.org/content/4/116/116ra6

      DOI: 10.1126/scitranslmed.3002902

    • Hope For Nonaddictive Opioid Painkillers | In the Pipeline

      MAR. 13, 2017

      Mar 13, 2017 … No one needs to be told about the opioid painkiller problem in this country. There are legal, commerical, regulatory, and ethical ways to look at it, but from a pharmacological standpoint, the whole thing would be a lot easier to deal with if there were any highly effective non-addictive painkillers. But that’s …

      • blogs.sciencemag.org/…/hope-for-nonaddictive-opioid-painkillers
    • EDITORS’ CHOICE

      Calcium Channels Brought Inside by Opioid-Like Receptor | Science …

      JAN. 2, 2006

      Nociceptin is an endogenous pain-alleviating peptide that binds to the receptor ORL1, which is structurally similar to opioid receptors. ORL1 was recently found to interact directly with N-type calcium channels, resulting in tonic, agonist-independent inhibition. Altier et al. extend these observations and report that extended …

      • stke.sciencemag.org/user/logout?current=node/188838

      DOI: 10.1126/stke.3162006tw460

    • Synergistic regulation of serotonin and opioid signaling contributes …

      JAN. 9, 2017

      Jan 10, 2017 … The balance of pronociceptive (pain-promoting) serotonin signaling mediated by the 5-HT4 receptor and antinociceptive (pain-relieving) opioid signaling mediated by the mu opioid receptor (MOR) was altered. Mice lacking Nav1.7 had much more efficient signaling by the opioid arm, shifting the balance …

      • stke.sciencemag.org/content/10/461/eaah4874
    • ARTICLES

      Opioid peptides endorphins in pituitary and brain | Science

      BY A GOLDSTEIN | SEP. 16, 1976

      Opioid peptides endorphins in pituitary and brain. See allHide authors and affiliations. Science 17 Sep 1976: Vol. 193, Issue 4258, pp. 1081-1086. DOI: 10.1126/science.959823. A Goldstein. Find this author on Google Scholar · Find this author on PubMed · Search for this author on this site · Article; Info & Metrics; eLetters …

      • science.sciencemag.org/content/193/4258/1081

      DOI: 10.1126/science.959823

    • REPORT

      Induction of Synaptic Long-Term Potentiation After Opioid Withdrawal

      BY RUTH DRDLA | JUL. 9, 2009

      Abstract. μ-Opioid receptor (MOR) agonists represent the gold standard for the treatment of severe pain but may paradoxically also enhance pain sensitivity, that is, lead to opioid-induced hyperalgesia (OIH). We show that abrupt withdrawal from MOR agonists induces long-term potentiation (LTP) at the first synapse in pain …

      • science.sciencemag.org/content/325/5937/207.full

      DOI: 10.1126/science.1171759

      Clear Submit search
      • Broad-Spectrum, Non-Opioid Analgesic Activity by Selective …

        JAN. 1, 1998

        Development of analgesic agents for the treatment of severe pain requires the identification of compounds that are devoid of opioid receptor liabilities. A potent (inhibition constant = 37 picomolar) neuronal nicotinic acetylcholine receptor (nAChR) ligand called ABT-594 was developed that has antinociceptive properties …

        • science.sciencemag.org/content/279/5347/77.full

        DOI: 10.1126/science.279.5347.77

      • REPORT

        Regional Mu Opioid Receptor Regulation of Sensory and Affective …

        JUL. 12, 2001

        The endogenous opioid system is involved in stress responses, in the regulation of the experience of pain, and in the action of analgesic opiate drugs. We examined the function of the opioid system and μ-opioidreceptors in the brains of healthy human subjects undergoing sustained pain. Sustained pain induced the …

        • science.sciencemag.org/content/293/5528/311.full

        DOI: 10.1126/science.1060952

      • Increased Abundance of Opioid Receptor Heteromers After Chronic …

        JUL. 19, 2010

        Abstract. The μ and δ types of opioid receptors form heteromers that exhibit pharmacological and functional properties distinct from those of homomeric receptors. To characterize these complexes in the brain, we generated antibodies that selectively recognize the μ-δ heteromer and blocked its in vitro signaling. With these …

        • stke.sciencemag.org/user/logout?current=node/191434
      • ASSOCIATION AFFAIRS

        S&T Policy Forum examines evolving opioid epidemic | Science

        BY KATHLEEN O’NEIL | APR. 27, 2017

        Apr 28, 2017 … Summary. More young people are using heroin, and powerful drug additives are causing more overdoses. Science: 356 (6336). Science. Vol 356, Issue 6336 28 April 2017. Table of Contents · Print Table of Contents · Advertising (PDF) · Classified (PDF) · Masthead (PDF). Article Tools. Email. Thank you for …

        • science.sciencemag.org/content/356/6336/390.1

        DOI: 10.1126/science.356.6336.390-a

      • Constitutive μ-Opioid Receptor Activity Leads to Long-Term …

        SEP. 19, 2013

        The properties and functions of µ-opioid receptors have been studied intensively with respect to the binding of endogenous or exogenous ligands. However, much less is known about the constitutive, ligand-independent, activation of opioid receptors. Working in mice, Corder et al. (p. 1394) observed the prolonged …

        • science.sciencemag.org/content/341/6152/1394.full
      • EDITORS’ CHOICE

        Paradoxical Pain After Opioid Withdrawal | Science Signaling

        BY PETER STERN | JUL. 13, 2009

        Opioids are widely used by both pain patients and substance abusers. Withdrawal from opioids can be complicated by opioid-induced hyperalgesia, a paradoxical amplification of pain by opioids. Drdla et al. detected a novel cellular opioid action that may help to explain this paradoxical pain: the induction of synaptic …

        • stke.sciencemag.org/content/2/79/ec240

        DOI: 10.1126/scisignal.279ec240

      • EDITORS’ CHOICE

        A Painful Endogenous Opioid | Science Signaling

        BY NANCY R. GOUGH | DEC. 4, 2006

        Dynorphin A1-17 is derived from proteolytic processing of prodynorphin and has high affinity for μ, δ, and κ opioid receptors. However, increased amounts of dynorphin A are found in models of chronic pain, and antibodies against dynorphin A alleviate, rather than potentiate, pain. Lai et al. show that a fragment of dynorphin …

        • stke.sciencemag.org/user/logout?current=node/188902

        DOI: 10.1126/stke.3642006tw407

      • Podcast: The impact of legal pot on opioid abuse, and a very early …

        NOV. 3, 2016

        Nov 3, 2016 … This week, news writer Greg Miller chats with us about how the legalization of marijuana in certain U.S. states is having an impact on the nation’s opioid problem. Plus, Sarah Crespi talks to Sascha Drewlo about a new method for profiling the DNA of fetuses very early on in pregnancy. [Image: …

        • http://www.sciencemag.org/…/podcast-impact-legal-pot-opioid-abuse-and-very- early-look-fetus-s-genome
      • LATEST NEWS

        Is a new class of painkillers on the horizon?

        BY ROBERT F. SERVICE | FEB. 27, 2017

        Feb 27, 2017 … Scientists are chasing a new lead on a class of drugs that may one day fight both pain and opioid addiction. It’s still early days, but researchers report that they’ve discovered a new small molecule that binds selectively to a long-targeted enzyme, halting its role in pain and addiction while not interfering with …

        • http://www.sciencemag.org/news/2017/02/new-class-painkillers-horizon
      • Synthesizing the Opioid Peptides

        Synthesizing the Opioid Peptides. The opioid peptides are synthesized as parts of large precursor molecules that may be split to yield different products in different cells. The biosynthesis of the opioid pep- tides illustrates what seemsto be a gen- eral trend in neurobiology. Likemany other peptides that act in the nervous.

        • science.sciencemag.org/content/sci/220/4595/395.full.pdf
Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:addiction, death, opioids, pain killersLeave a comment on Opioid addiction—degrades health, saps productivity, spawns crime, and devastates families

Suppressed dopaminergic activity in a specific brain area may play a causal role in depression

Suppressed dopaminergic activity in a specific brain area may play a causal role in depression.

Major depressive disorder (MDD) is a heterogenous mental illness characterized by deficits in mood and reward processing. The ventral tegmental area (VTA) of the brain plays a critical role in regulating reward processing via its projection to the nucleus accumbens (NAc), and altered cellular function in VTA has been implicated in mediating depression. In a recent study, Zhong et al. begin to elucidate the cellular and molecular mechanisms underlying the dysregulation of VTA in depression. Using the widely validated chronic mild stress (CMS) mouse model, the authors verified that the depression-like behavior observed in this model is linked to decreased neuronal firing in the VTA.

The hyperpolarization-activated cation current (Ih), mediated by hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) channels, increases VTA firing. First, the authors tested whether Ih was suppressed in mice subjected to CMS by analyzing ex vivo brain slices. They discovered that in CMS-exposed mice, this current was suppressed in NAc-projecting VTA dopamine neurons, a pathway central to reward processing. The authors then demonstrated that pharmacological blockade of Ih suppressed VTA firing to a lesser extent in mice exposed to CMS than in nonstressed controls, providing additional evidence that decreased Ih contributed to the decreased VTA dopamine neuron firing observed in the CMS model.

Next, to determine whether suppression of Ih was sufficient to induce depression-like behavior, the authors applied a virally mediated RNA interference strategy. Knocking down HCN2 suppressed Ih and induced depression-like behavior in nonstressed mice. Conversely, virally mediated overexpression of HCN2 increased Ih and rendered animals resistant to the depression-inducing effects of CMS.

Together, these findings demonstrate that CMS-induced depression-like behavior is at least partially mediated by decreased Ih in VTA dopaminergic neurons. Interestingly, earlier findings in mice exposed to chronic social defeat stress, another widely validated mouse model of depression, found that depression-like behavior was mediated by an increase in Ih. Thus, although both models suggest that dysregulation of VTA dopamine activity is central, further experiments will be necessary to determine the broader neural mechanisms whereby increases or decreases in VTA dopaminergic activity can converge to yield a common set of depression-related behavioral deficits.

Highlighted Article

    1. P. Zhong,
    2. C. R. Vickstrom,
    3. X. Liu,
    4. Y. Hu,
    5. L. Yu,
    6. H. -G. Yu,
    7. Q. -S. Liu

    , HCN2 channels in the ventral tegmental area regulate behavioral responses to chronic stress. eLife 7, e32420 (2018).

    Google Scholar
    ————-

Dopamine rich foods

  • Dairy foods such as milk, cheese and yogurt.
  • Unprocessed meats such as beef, chicken and turkey.
  • Omega-3 rich fish such as salmon and mackerel.
  • Eggs.
  • Fruit and vegetables, in particular bananas.
  • Nuts such as almonds and walnuts.
  • Dark chocolate.

Ways to increase dopamine

How to Increase Dopamine Naturally | Be Brain Fit

https://bebrainfit.com/increase-dopamine/

lack of motivation; fatigue; apathy; procrastination; inability to feel pleasure; low libido; inability to connect with others; sleep problems; mood swings; hopelessness; memory loss; inability to …. Sunlight can increase the number of dopamine receptors and create vitamin D which activates the genes that release dopamine.

Dopamine Deficiency: 8 Ways to Naturally Overcome Depression …

https://universityhealthnews.com/…/8-natural-dopamine-boosters-to-overcome-depres&#8230;

Treating a dopamine deficiency can help you take back your health! How? First, you need to understand that depression is a disease that can be caused by a dopamine deficiency. In many cases, it is caused by actual physiologic changes in your brain. Therefore, when you feel depressed, don’t think of it as a defect in your …

Dopamine & Insomnia | LIVESTRONG.COM

https://www.livestrong.com › Diseases and Conditions

Aug 14, 2017 – When you struggle to get a good night’s sleep, it can affect your brain. As little as one night of lost sleep may affect your levels of dopamine in your brain. … According to Thomas Roth, Ph.D., in the “Journal of Clinical Sleep Medicine,” a disorder is a condition associated with negative consequences, and …

The Life Extension Blog: Is There a Link Between Vitamin D and …

blog.lifeextension.com/2012/01/link-between-vitamin-d-depression.html

Jan 24, 2012 – By Maylin Rodriguez-Paez Vitamin D , along with diet and exercise, has emerged as one of the most important preventive factors i. … discovered that in cultured adrenal cells vitamin D increased the expression of tyrosine hydroxylase, which is the rate limiting enzyme responsible fordopamine production.9 …

3 Ways to Increase Dopamine – wikiHow

https://www.wikihow.com/Increase-Dopamine

Exercise regularly. Exercise increases blood calcium, which stimulates dopamine release and uptake in your brain. Try 30 to 60 minutes of walking, swimming or jogging to … Get plenty of sleep. One of the best ways to feel energized and ready to tackle the day is to get plenty of sleep. Dopamine has been tied to feelings of …

Neurotransmitters and Prolonged Exercise – Robb Wolf

robbwolf.com/2012/12/05/neurotransmitters-prolonged-exercise/

Dec 5, 2012 – Studies showed that exercise caused an increase of serotonin precursors, as well asdopamine, in the brainstem and the hypothalamus. These researchers stated that … If we lack sleep, are stressed, vitamin D deficient, etc. it may be a good idea to not exercise too strenuously. Also, we need to manage our …

Sunlight and Vitamin D improve mood | DrDobbin Nutrition

http://www.drdobbin.co.uk/sunlight-vitamin-d

Jan 11, 2011 – Sunlight exposure can benefit mood by boosting levels of key hormones and also by producing vitamin D. Vitamin D is produced in the liver and … So having increased dopamine levels should make you feel more euphoric and this is likely to be the pleasure we feel when we open the windows on a sunny …

One Sleepless Night Increases Dopamine In The Human Brain …

https://www.sciencedaily.com/releases/2008/08/080819213033.htm

Aug 21, 2008 – Just one night without sleep can increase the amount of the chemical dopamine in the human brain, according to new imaging research in the Journal of Neuroscience. Because drugs thatincrease dopamine, like amphetamines, promote wakefulness, the findings offer a potential mechanism explaining …

Sleep Deprived? Mind your dopamine. – Scientific American Blog …

https://blogs.scientificamerican.com/scicurious…/sleep-deprived-mind-your-dopamine&#8230;

Jun 4, 2012 – “Evidence That Sleep Deprivation Downregulates Dopamine D2R in Ventral Striatumin the Human Brain” Journal of Neuroscience, 2012. There are lots of signs that point toward the involvement of the neurotransmitter dopamine in wakefulness. Drugs that increase levels of dopamine in brain (including, …

Boosting Your Serotonin Activity | Psychology Today

https://www.psychologytoday.com/blog/prefrontal…/boosting-your-serotonin-activity

Nov 17, 2011 – The four ways to boost serotonin activity are sunlight, massage, exercise, and remembering happy events. At this point … However, UV is important because UV light absorbed through your skin produces Vitamin D. Vitamin D plays many roles in your body, including promotingserotonin production. 

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:depression, dopamine, dopamine diet, exercise, food, sleepLeave a comment on Suppressed dopaminergic activity in a specific brain area may play a causal role in depression

Volunteer arrested hours after his group exposed Border Patrol dumping water left for migrants 

  • Justin Trudeau had an announcement for Trump in Davos
  • The fiancé of former Trump aide Papadopoulos warns White House: ‘There’s a lot to come’
  • Smell the panic
  • Daily Kos is resisting Trump every single day. Can you chip in $1 to support independent, progressive media?
  • Explosive video: After a man threatened to kill CNN employees, Don Lemon spoke directly to Trump
  • Cartoon: Worse than Idiocracy
  • Women reporting on Mike Pence’s Israel trip forced into second-class status behind a fence
  • Female staffer says PA congressman lashed out after she rejected him, he blames Obamacare
  • Volunteer arrested hours after his group exposed Border Patrol dumping water left for migrants
  • Neil Gorsuch must recuse himself from DACA case after political talks with Senate GOP leadership
  • Sign the petition: Stop Republican purge of Mueller investigation.
  • Feds arrest Michigan man who planned to travel to Atlanta to massacre CNN employees
  • Married Republican congressman, accused of sexual harassment, says aide was his ‘soulmate’
  • BOOM! Schumer withdraws offer to give Trump his wall: ‘We start from a blank sheet of paper’
  • House Science Committee wants to investigate scientist for reporting science for the government
  • Trump’s sham voter commission asked Texas to flag ‘all Hispanic surnames’ in voter records
  • The Daily Kos Elections legislative open seat tracker shows Republicans are headed for the hills
Posted byconnie dello buonoJanuary 24, 2018Posted inPoliticsLeave a comment on Volunteer arrested hours after his group exposed Border Patrol dumping water left for migrants 

Drug prescribing for older adults in the USA

Drug prescribing for older adults

Author:
Paula A Rochon, MD, MPH, FRCPC
Section Editor:
Kenneth E Schmader, MD
Deputy Editor:
Daniel J Sullivan, MD, MPH

Contributor Disclosures

All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Dec 2017. | This topic last updated: May 26, 2017.

INTRODUCTION — Optimizing drug therapy is an essential part of caring for an older person. The process of prescribing a medication is complex and includes: deciding that a drug is indicated, choosing the best drug, determining a dose and schedule appropriate for the patient’s physiologic status, monitoring for effectiveness and toxicity, educating the patient about expected side effects, and indications for seeking consultation.

Avoidable adverse drug events (ADEs) are the serious consequences of inappropriate drug prescribing. The possibility of an ADE should always be borne in mind when evaluating an older adult individual; any new symptom should be considered drug-related until proven otherwise.

Prescribing for older patients presents unique challenges. Premarketing drug trials often exclude geriatric patients and approved doses may not be appropriate for older adults [1]. Many medications need to be used with special caution because of age-related changes in pharmacokinetics (ie, absorption, distribution, metabolism, and excretion) and pharmacodynamics (the physiologic effects of the drug).

Particular care must be taken in determining drug doses when prescribing for older adults. An increased volume of distribution may result from the proportional increase in body fat relative to skeletal muscle with aging. Decreased drug clearance may result from the natural decline in renal function with age, even in the absence of renal disease [2]. Larger drug storage reservoirs and decreased clearance prolong drug half-lives and lead to increased plasma drug concentrations in older people.

As examples, the volume of distribution for diazepam is increased, and the clearance rate for lithium is reduced, in older adults. The same dose of either medication would lead to higher plasma concentrations in an older, compared with younger, patient. Also, from the pharmacodynamic perspective, increasing age may result in an increased sensitivity to the effects of certain drugs, including benzodiazepines [3-6] and opioids [7].

Hepatic function also declines with advancing age, and age-related changes in hepatic function may account for significant variability in drug metabolism among older adults [8]. Especially when polypharmacy is a factor, decreasing hepatic function may lead to adverse drug reactions (ADRs).

A stepwise approach to optimized prescribing of drug therapy for older adults will be reviewed here. Drug treatments for specific conditions in the older population are discussed separately.

MEDICATION USE BY OLDER ADULTS — Medications (prescription, over-the-counter, and herbal preparations) are widely used by older adults.

Prescription medications — A survey in the United States of a representative sampling of 2206 community-dwelling adults (aged 62 through 85 years) was conducted by in-home interviews and use of medication logs between 2010 and 2011 [9]. At least one prescription medication was used by 87 percent. Five or more prescription medications were used by 36 percent, and 38 percent used over-the-counter medications.

In a sample of Medicare beneficiaries discharged from an acute hospitalization to a skilled nursing facility, patients were prescribed an average of 14 medications, including over one-third with side effects that could exacerbate underlying geriatric syndromes [10].

Herbal and dietary supplements — Use of herbal or dietary supplements (eg, ginseng, ginkgo biloba extract, and glucosamine) by older adults has been increasing, from 14 percent in 1998 [11] to 63 percent in 2010 [9]. One study in over 3000 ambulatory adults 75 years of age or older in four states in the United States found that almost three-quarters used at least one prescription drug and one dietary supplement [12]. Often, clinicians do not question patients about use of herbal medicines and patients do not routinely volunteer this information. In one United States survey, three-quarters of respondents aged 18 years and older reported that they did not inform their clinician that they were using unconventional medications [13].

Herbal medicines may interact with prescribed drug therapies and lead to adverse events, underscoring the importance of routinely questioning patients about the use of unconventional therapies. Examples of herbal-drug therapy interactions include ginkgo biloba extract taken with warfarin, causing an increased risk of bleeding, and St. John’s wort taken with serotonin-reuptake inhibitors, increasing the risk of serotonin syndrome in older adults [14]. A study of the use of 22 supplements in a survey of 369 patients aged 60 to 99 years found potential interactions between supplements and medications for 10 of the 22 supplements surveyed [15]. (See “Overview of herbal medicine and dietary supplements”, section on ‘Herb-drug interactions’.)

Many older adults receive their information about herbal products from the internet. Eighty percent of 338 retail web sites identified in a search of the eight most widely used herbal supplements (ginkgo biloba, St. John’s wort, echinacea, ginseng, garlic, saw palmetto, kava, and valerian root) made at least one health claim suggesting that the therapy could treat, prevent, or even cure specific conditions [16].

QUALITY MEASURES OF DRUG PRESCRIBING — Multiple factors contribute to the appropriateness and overall quality of drug prescribing. These include avoidance of inappropriate medications, appropriate use of indicated medications, monitoring for side effects and drug levels, avoidance of drug-drug interactions, and involvement of the patient and integration of patient values [17].

Measures of the quality of prescribing often focus on one or some of these factors, but rarely on all. Furthermore, the predictive value of these measures of “quality of prescribing” in determining important long-term outcomes of care have not been determined. Approaches to decrease inappropriate prescribing in older adults include educational interventions, computerized order entry and decision support, multidisciplinary team care led by physicians, clinical pharmacists, and combinations of these approaches. Available data for these interventions generally show significant improvements in inappropriate prescribing but mixed results for health outcomes or costs [17,18]. A 2016 systematic review of eight studies of different prescribing interventions in long-term care homes (medication review, case conferences, staff education, clinical decision support technology, and/or some combination of these) showed no effect of the interventions on hospital admissions, adverse drug events (ADEs), and mortality [18]. The studies that evaluated medication-related problems, appropriate prescribing, or cost of medication showed some evidence that interventions helped the recognition and solving of medication problems. A previous 2008 systematic review of 10 studies of computerized physician order entry with clinical decision support showed a mixed effect on reduction in ADEs, with five studies that showed a statistically significant reduction in ADEs, four that showed nonsignificant decrease, and one study that showed no impact on rate of ADEs [19].

POLYPHARMACY — Polypharmacy is defined simply as the use of multiple medications by a patient. The precise minimum number of medications used to define “polypharmacy” is variable, but generally ranges from 5 to 10 [20]. While polypharmacy most commonly refers to prescribed medications, it is important to also consider the number of over-the-counter and herbal/supplements used.

The issue of polypharmacy is of particular concern in older people who, compared with younger individuals, tend to have more disease conditions for which therapies are prescribed. It has been estimated that 20 percent of Medicare beneficiaries have five or more chronic conditions and 50 percent receive five or more medications [21]. Among ambulatory older adults with cancer, 84 percent were receiving five or more and 43 percent were receiving 10 or more medications, in one study [22].

The use of greater numbers of drug therapies has been independently associated with an increased risk for an adverse drug event (ADE), irrespective of age [23], and increased risk of hospital admission [24,25]. However, it is difficult to eliminate the impact of confounding factors in considering the relationship between polypharmacy and a variety of outcomes in observational studies [26].

There are multiple reasons why older adults are especially impacted by polypharmacy:

●Older individuals are at greater risk for ADEs due to metabolic changes and decreased drug clearance associated with aging; this risk is compounded by increasing numbers of drugs used.

●Polypharmacy increases the potential for drug-drug interactions and for prescription of potentially inappropriate medications [27].

●Polypharmacy was an independent risk factor for hip fractures in older adults in one case-control study, although the number of drugs may have been an indicator of higher likelihood of exposure to specific types of drugs associated with falls (eg, central nervous system [CNS]-active drugs) [28].

●Polypharmacy increases the possibility of “prescribing cascades” [29]. A prescribing cascade develops when an ADE is misinterpreted as a new medical condition and additional drug therapy is then prescribed to treat this medical condition. (See ‘Prescribing cascades’ below.)

●Use of multiple medications can lead to problems with adherence in older adults, especially if compounded by visual or cognitive impairment. A 2017 systematic review of observational studies suggested that drug regimen complexity is associated with medication nonadherence [24].

A balance is required between over- and under-prescribing. Multiple medications are often required to manage clinically complex older adults. Clinicians are often challenged with the need to match the complex needs of their older patients with those of disease-specific clinical practice guidelines. For a hypothetical older female patient with chronic obstructive pulmonary disease, type 2 diabetes, osteoporosis, hypertension, and osteoarthritis, clinical practice guidelines would recommend prescribing 12 medications for this individual [30].

A more systematic approach is required to guide the tailoring of medication regimens to the needs of individuals. One important principle is to match the medication regimen to the patient’s condition and goals of care. This includes a careful consideration of the medications that should be discontinued or substituted [31] (table 1).

It is particularly important to reconsider medication appropriateness late in life. A model for appropriate prescribing for patients late in life has been proposed [32] (table 2). The process considers the patients’ remaining life expectancy and the goals of care in reviewing the need for existing medications and in making new prescribing decisions. For example, if a patient’s life expectancy is short and the goals of care are palliative, then prescribing a prophylactic medication requiring several years to realize a benefit may not be considered appropriate. This is increasingly being recognized as an important consideration when managing individuals with advanced dementia [33]. Additionally, therapeutic medications (eg, antibiotics for pneumonia) may not increase comfort or quality of life when palliative care is the objective [34].

INAPPROPRIATE MEDICATIONS — Various criteria have been developed by expert panels in Canada [35] and in the United States [36-41] to assess the quality of prescribing practices and medication use in older adult individuals. The most widely used criteria for inappropriate medications are the Beers criteria. (See ‘Beers criteria’ below.)

In another approach, a Drug Burden Index has been modelled incorporating drugs with anticholinergic or sedative effects, total number of medications, and daily dosing [42,43]. An increased drug burden for anticholinergic and sedative medications was associated with impaired performance on mobility and cognitive testing in high-functioning community-based older adults. Zolpidem, in particular, was implicated in 21 percent of emergency department visits for adverse drug events (ADEs) related to psychiatric medication among adults 65 years and older [44].

Total number of medications was not associated with impaired performance when sedatives and anticholinergics were excluded [42,43]. A high Drug Burden Index has been correlated with increased risk for functional decline in community dwellers [43] and with increased risk of falls in residents in long-term care facilities [45].

Anticholinergic activity — Anticholinergic medications are associated with multiple adverse effects to which older individuals are particularly susceptible. Nonetheless, an analysis of United States medication expenditures between 2005 and 2009 found that 23.3 percent of community-dwelling persons >65 years with dementia were prescribed medications with clinically significant anticholinergic activity (AA) [46].

Adverse effects associated with anticholinergic use in older adults include memory impairment, confusion, hallucinations, dry mouth, blurred vision, constipation, nausea, urinary retention, impaired sweating, and tachycardia. A case-control study found an association between anticholinergic use and risk of community-acquired pneumonia [47]. Anticholinergics can precipitate an acute glaucoma episode in patients with narrow angle glaucoma and acute urinary retention in patients with benign prostatic hypertrophy. Specific studies of the relationship between dementia and anticholinergic use include the following:

●In a population study of 6912 men and women 65 years and older, those taking anticholinergic drugs were at increased risk for cognitive decline and dementia and risk decreased with medication discontinuation [48].

●In a population of 3434 men and women age 65 and older in one health care setting, who had no baseline dementia and who were followed for 10 years, the risk of dementia and Alzheimer’s disease increased in a dose-response relationship with use of anticholinergic drug classes (primarily first-generation antihistamines, tricyclic antidepressants, and bladder antimuscarinics) [49].

●In another population of 13,004 individuals aged 65 and older, use of anticholinergic medications was also shown to be associated with greater decline in cognition as measured by the Mini-Mental State Examination [50]. In addition, anticholinergic medication use was associated with increased mortality over a two-year period after adjustment for multiple factors, including comorbid health conditions.

Multiple scales, including the Drug Burden Index [42], have been developed to identify the anticholinergic burden of medications. For nine scales evaluated in one study, a higher score was associated with increased risk for hospitalization and length of stay, falls, and medical utilization [51]. A listing of medication classes that contain significant AA is shown in a table (table 3).

A study measured the in vitro AA of 107 medications commonly used in older adults [52]. At usual doses, AA was most significantly elevated for amitriptyline, atropine, clozapine, dicyclomine, doxepin, L-hyoscyamine, thioridazine, and tolterodine. AA also was increased for chlorpromazine, diphenhydramine, nortriptyline, olanzapine, oxybutynin, and paroxetine. It should be noted, however, that higher doses of an agent with relatively low or moderate AA can produce significant AA effects. Additionally, the cumulative effects of more than one agent with low AA can produce significant AA effects.

Alternative drugs with lower AA are available in many classes represented by these drugs. However, adverse drug reactions (ADRs) other than AA should also be taken into account in weighing the clinical benefits of possible substitutions (eg, dyskinesias and sedation with haloperidol and perphenazine).

Beers criteria — The Beers criteria, initially developed by an expert consensus panel in 1991 to target nursing home residents, are the most widely cited criteria used to assess inappropriate drug prescribing [36]. The panel produced a list of medications considered inappropriate for older patients, either because of ineffectiveness or high risk for adverse events.

The original Beers criteria have been revised in 1997, 2003, 2012, and most recently in 2015 [37,38,53,54]. The 2015 revised Beers criteria are available through the American Geriatrics Society website. The criteria include over 50 medications designated in one of three categories: those that should always be avoided (eg, barbiturates, chlorpropamide); those that are potentially inappropriate in older adults with particular health conditions or syndromes; and those that should be used with caution. New additions since 2012 are a table of non-antiinfective drug interactions and a table of non-antiinfective medications to avoid or adjust for decreased renal function [54]. Some notable changes in the 2015 listings are removal of loratadine from the list of medications with strong anticholinergic properties; a more liberal renal threshold (now creatinine clearance <30 rather than <60 mL/min) for withholding nitrofurantoin; avoidance of long-term proton pump inhibitors because of risk of Clostridium difficileinfections and bone loss; and stricter guidelines to avoid antipsychotics for behavioral problems unless other options have failed and the older adult is threatening harm to self or others.

Several studies, using older versions of the Beers criteria, have identified that use of drugs identified as “inappropriate” was widespread in the United States, Canada, and Europe [55-57]. In a sample of community-dwelling older adults in the United States, 43 percent used at least one medication that would be deemed potentially inappropriate by the updated Beers criteria, with nonsteroidal antiinflammatory drugs (NSAIDs) being the most common [58]. Another study, using Medicare data and the 2012 Beers criteria, found that the point prevalence in each calendar month of potentially inappropriate medications used in adults ≥65 years was 34.2 percent in 2012 [59].

Some of the inappropriate drug therapies identified on the Beers list are available as over-the-counter products [60]. This reinforces the need to always consider over-the-counter drug therapies when reviewing a patient’s medications and to educate individuals on potential problems that can arise from the use of over-the-counter preparations.

The Beer’s criteria are increasingly being used to monitor quality of care for older adults. The validity of these consensus-derived criteria in predicting adverse outcomes therefore is becoming increasingly more important. Studies of earlier versions of the Beers criteria found that while the criteria did predict adverse outcomes, some medications that were not on the earlier criteria correlated more closely with adverse outcomes:

●Data from the 1996 Medical Expenditure Panel survey showed that risks of hospitalization and death were greater for nursing home patients who had been prescribed medications defined as potentially inappropriate by the 2003 combined Beers criteria [61].

●A systematic review of 18 retrospective cohort studies found that for patients >65 years old in the community setting, inappropriate medication use (defined by Beers criteria 1991, 1997, and 2003) was associated with increased hospitalization rates but not mortality; for patients in the nursing home setting, the relationship between inappropriate medications and hospitalization rates was inconclusive [62].

●A study that used electronic data to survey ADEs associated with emergency department visits for patients ≥ 65 years of age found that drugs meeting Beers criteria for always potentially inappropriate accounted for 3.6 percent (95% CI 2.8-4.5 percent) of the estimated 178,000 visits [63]. Three medications not on the Beers list at the time of the study (warfarin, digoxin, and insulin) accounted for 33.3 percent (95% CI 27.8-38.7 percent) of the visits, and medications in the general class of anticoagulants or antiplatelet agents, antidiabetic agents, and narrow therapeutic index agents accounted for nearly half of all visits, though were prescribed in only 9.4 percent of patients seen.

●Similar methodology was used by the same group to evaluate ADEs resulting in emergency hospitalizations among older Americans [64]. Four types of medication (warfarin, insulin, oral antiplatelet agents, and oral hypoglycemics) accounted for 67.0 percent of the ADEs, while 6.6 percent of the hospitalizations were attributed to Beers-criteria potentially inappropriate medications.

Other criteria sets — The Screening Tool of Older Person’s Prescriptions (STOPP) criteria, another tool for identifying inappropriate prescribing, were introduced in 2008 [65-67]. The 2003 Beers criteria have been compared with the Screening Tool of Older Person’s Prescriptions (STOPP); STOPP and Beers criteria overlapped in several areas, but earlier versions of the Beers criteria used in this comparison contained some drugs no longer in common use, and STOPP includes consideration of drug-drug interactions and duplication of drugs within a class. In two studies, STOPP identified a significantly higher proportion of older people requiring hospitalization as a result of a medication-related adverse event than did the 2003 Beers criteria [65,67]. In a cluster randomized trial in Ireland, presenting attending physicians with potentially inappropriate medications based on the STOPP/START (Screening Tool to Alert doctors to the Right Treatment) criteria reduced the number of adverse drug events and medication costs during the index hospitalization, but did not reduce length of stay [68].

The FORTA (Fit FOR The Aged) list identifies medications rated in four categories (clear benefit; proven but limited efficacy or some safety concerns; questionable efficacy or safety profile, consider alternative; clearly avoid and find alternative) with ratings based on the individual patient’s indication for the medication [69]. The tool, developed in Germany, has undergone consensus validation with a panel of geriatricians [70], but studies of its impact on clinical outcomes are ongoing.

Health care financing administration — The Centers for Medicare and Medicaid Services drug utilization review criteria target eight prescription drug classes (digoxin, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, H2 receptor antagonists, NSAIDs, benzodiazepines, antipsychotics, and antidepressants) and focus on four types of prescribing problems (inappropriate dose, inappropriate duration of therapy, duplication of therapies, and potential for drug-drug interactions). In one study, 19 percent of 2508 community-dwelling older adults were using one or more medications inappropriately; NSAIDs and benzodiazepines were the drug classes with the most potential problems [40].

Assessing Care of Vulnerable Elders project — Another expert panel has identified quality indicators for appropriate medication use as part of the Assessing Care of Vulnerable Elders (ACOVE) project [71,72]. These indicators begin with practical suggestions on how to improve prescribing practices:

●Document the indication for a new drug therapy

●Educate patients on the benefits and risks associated with the use of a new therapy

●Maintain a current medication list

●Document response to therapy

●Periodically review the ongoing need for a drug therapy

In addition, these indicators specify drug therapies that either should not be prescribed for older adults or that warrant careful monitoring after they have been initiated (table 4).

UNDERUTILIZATION OF APPROPRIATE MEDICATION — Much attention has been paid to over-prescribing for older adults; under-prescribing appropriate medications is also of concern. Prescribing strategies that seek to simply limit the overall number of drugs prescribed to older adults in the name of improving quality of care may be seriously misdirected.

Clinicians may be better at avoiding over-prescribing of inappropriate drug therapies than at prescribing indicated drug therapies. As an example, one study of older adults (n = 372) in two managed care organizations found that 50 percent had not been prescribed some recommended therapy, while only 3 percent were prescribed medications classified as inappropriate [73]. However, under- and overutilization of medications were equally prevalent in another study [74]. In a US Department of Veterans Affairs (VA) outpatient population, mean age 75 years (n = 196), inappropriate medications were documented for 65 percent and medication underuse for 64 percent; simultaneous under and overutilization occurred in 42 percent of patients.

START (Screening Tool to Alert doctors to the Right Treatment) is a set of 22 validated criteria, developed by a consensus process involving experts in geriatric pharmacotherapy, aimed to identify potential prescribing omissions in older hospitalized patients [75]. One or more potential prescribing omissions was identified in nearly 60 percent of patients in one study.

However, it should also be recognized that determination of “under-prescribing” is based on guidelines that address individual disease entities, while most geriatric patients have multiple conditions [21]. As an example, a patient with a myocardial infarction, history of diabetes, and elevated lipids would require a beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aspirin, statin, and a hypoglycemic medication. Accordingly, many older adults need to take six or more essential medications. In this context, clinicians may make informed decisions to “under-prescribe” to foster compliance with essential medications, limit drug interactions, and prioritize health benefits for active treatment of serious conditions over preventive therapies or conditions that have less impact on quality of life.

Factors leading to unintended underutilization include clinicians not recognizing medication benefit in the older population, affordability, and dose availability.

Medication effectiveness — Studies of drug effectiveness specifically often exclude the geriatric population due to concerns with comorbidities and side effects, causing difficulty in interpretation of study results. Therefore, the benefit of treatment for older adults, especially for preventive purposes, may not be established or may not be recognized by prescribing clinicians. As an example, in a study of statin use for secondary prevention in patients over age 66, the likelihood of being prescribed statin therapy declined 6.4 percent for every year of age; overall, only 19 percent of patients in this high-risk population had been prescribed a statin [76].

Affordability — A prescription may be written but not filled, or filled and not taken regularly, due to financial considerations. This may be a particular problem in countries where there is no universal insurance coverage for drug therapy for older adults.

Enhanced drug coverage for older adults can be a powerful incentive to improve the use of beneficial therapies. A comparison of two groups of Medicare patients, as an example, found that statin use was 4.1 percent in patients without drug coverage and 27 percent in those with drug benefits [77]. Significant utilization differences between insured and uninsured patients were seen even for the use of inexpensive medications such as beta-blockers and nitrates.

Cost-related medical noncompliance affected almost 30 percent of disabled Medicare enrollees in 2004, and noncompliance rates were significantly higher for patients with multiple comorbidities [78].

Additional information on the affordability of medications can be found elsewhere in UpToDate. (See “Patient education: Reducing the costs of medicines (Beyond the Basics)”.)

Dose availability — Older individuals often require lower than usual doses of medications, especially at initiation. If medications are not readily available in prescribed doses, the need to split tablets may make it more difficult for patients to take beneficial drug therapy [79].

ADVERSE DRUG EVENTS — A number of factors in older individuals contribute to their increased risk for developing a drug-related problem. These include frailty, coexisting medical problems, memory issues, and use of multiple prescribed and non-prescribed medications [80].

Drug-related hospitalizations account for 2.4 to 6.5 percent of all medical admissions in the general population; the proportion is much higher for older patients [81-83]. In the United States, it is estimated that annually from 2007 to 2009 there were 99,628 emergency hospitalizations for adverse drug events (ADEs) in individuals 65 years and older, with two-thirds due to unintentional overdoses [64]. A meta-analysis found a fourfold increase in the rate of hospitalization related to ADEs in older adults compared with younger adults (16.6 versus 4.1 percent); it was estimated that 88 percent of the ADE hospitalizations among older adults were preventable, compared with 24 percent among young persons [84].

Adverse drug reactions (ADRs) are noxious responses to drugs used in usual doses for treatment or prevention of disease. ADEs are any injury that occurs from a drug, including noxious responses, drug administration errors, and any other circumstances that lead to an injury.

Prescribing cascades — Prescribing cascades occur when a new drug is prescribed to treat symptoms arising from an unrecognized ADE related to an existing therapy [29]. The patient is then at risk for developing additional ADEs related to the new and potentially unnecessary treatment (table 5). Older adults with chronic disease and multiple drug therapies are at particular risk for prescribing cascades.

Drug-induced symptoms in an older person can be easily misinterpreted as indicating a new disease or attributed to the aging process itself rather than the drug therapy. This misinterpretation is particularly likely when the drug-induced symptoms are indistinguishable from illnesses that are common in older persons. Selected examples of prescribing cascades are described below.

●One of the best recognized examples of a prescribing cascade relates to the initiation of anti-Parkinson therapy for symptoms arising from use of drugs such as antipsychotics [85-87] or metoclopramide [88]. The anti-Parkinson drugs can then lead to new symptoms, including orthostatic hypotension and delirium.

In a case-control study of 3512 Medicaid patients (age 65 to 99 years), patients who had received an antipsychotic medication in the preceding 90 days were 5.4 times more likely to be prescribed anti-Parkinson therapy than patients who had not received an antipsychotic (95% CI 4.8-6.1) [85].

●Some prescribing cascades may be less obvious, especially for drugs whose adverse events are not as commonly recognized. As an example, cholinesterase inhibitors (eg, donepezil, rivastigmine, and galantamine) are commonly used for the management of dementia symptoms in older adults. The adverse events associated with these drugs can be viewed as the reverse of those that might be expected with anticholinergic therapies. Accordingly, while anticholinergic therapies may cause constipation and urinary retention, cholinesterase inhibitors may cause diarrhea and urinary incontinence. A prescribing cascade occurs when the prescription of a cholinesterase inhibitor is followed by a prescription for an anticholinergic therapy (eg, oxybutynin) to treat incontinence.

A retrospective cohort study in older adults in Canada (n = 44,884) found that the risk of treatment with an anticholinergic medication for urinary incontinence was greater for patients who had received a cholinesterase inhibitor (adjusted hazard ratio 1.53; 95% CI 1.39-1.72) [89]. This study suggests that clinicians should consider the possible contributing role of cholinesterase inhibitors in new-onset or worsening urinary incontinence.

Drug-drug interactions — Older adults are particularly vulnerable to drug-drug interactions because they often have multiple chronic medical conditions requiring multiple drug therapies. The risk of an adverse event due to drug-drug interactions is substantially increased when multiple drugs are taken [90-94]. As an example, the risk of bleeding with warfarin therapy is increased with coadministration of selective and nonselective nonsteroidal antiinflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil [90].

A case control study from Canada evaluated hospitalizations for drug-related toxicity in a population of older patients who had received one of three drug therapies: glyburide, digoxin, or angiotensin-converting enzyme (ACE) inhibitor [94]. Hospitalization for hypoglycemia was six times more likely in patients who had received co-trimoxazole. Digoxin toxicity was 12 times more likely for patients who had been started on clarithromycin. Hyperkalemia was 20 times more likely for patients who were treated with a potassium-sparing diuretic.

Care must be taken when prescribing any medication, especially for the older individual, to review existing medications and consider potential drug interactions.

Dose-related adverse drug events — ADEs are often dose-related. Examples include:

●A case-control study from the 1980s related risk of hip fracture in a Medicaid population with use and dose of psychotropic drugs [95]. A dose-related effect was seen for use of long half-life hypnotic-anxiolytics, tricyclic antidepressants, or neuroleptic therapy, and hospitalization for hip fracture.

●A study of people 65 years and older in Quebec (n >250,000) found that more than a quarter (27.6 percent) were dispensed at least one prescription for a benzodiazepine [96]. The risk of injury was dose-related for some benzodiazepines (oxazepam, flurazepam, and chlordiazepoxide), though not for alprazolam.

●Dose of benzodiazepine, but not elimination half-life, was related to risk for hip fracture in a case-control study of adults aged 55 years and older from the Netherlands [6].

Renal impairment — A common cause of dose-related adverse events in older adults is failure to properly adjust doses for renal insufficiency. Renal impairment becomes more common with advancing age. For patients with stable renal function, creatinine clearance can be estimated according to published formulas which factor age into the calculation (calculator 1). Because of decreased muscle mass in older adults, however, serum creatinine levels may not adequately reflect renal function; many older patients with a normal creatinine nonetheless have modestly impaired renal function. In one study, 40 percent of almost 10,000 older adults living in long-term care were found to have renal insufficiency [97]. In a community population over age 65 in France, the prevalence of renal insufficiency (estimated glomerular filtration rate [GFR] <60 mL/min/1.73 m2) was 13.7 percent using the MDRD equation and 36.9 percent using the Cockcroft-Gault formula [98]. (See “Assessment of kidney function”.)

Dosing guidelines for decreased creatinine clearance are available to calculate dose adjustments for medications that are cleared through the kidney [99]. The list of medications is long and includes many antibiotics. In a community population, 52 percent of adults over age 65 with mild renal insufficiency were taking medications that required dose adjustment for low GFR; antihypertensives, fibrates, sedative/hypnotic, and anxiolytic medications accounted for most of these drugs [98]. The drug database (Lexi-Comp) available through UpToDate includes appropriate dose adjustments for renal function and for older adults, and can be accessed by searching on any individual drug. As a general rule, the initial dose for starting medications in older adults should be significantly reduced, and titrated up as tolerated by monitoring side effects or drug levels.

Decision aids have been moderately effective in decreasing the percentage of in-hospital prescriptions written with inappropriate adjustments for renal status (46 to 33 percent) [100].

Adverse drug events in long-term care setting — Long-term care residents are at a particularly high risk for developing adverse events [101]. The average United States nursing home resident uses seven to eight different medications each month, and about one-third of residents have monthly drug regimens of nine or more medications [102].

A study of ADEs in two large academic long-term care facilities in the United States and Canada found 815 ADEs occurring during 8336 resident months [101]. The overall rate of ADEs was 9.8 per 100 resident–months; 42 percent of the ADEs were deemed preventable. Of the more serious adverse events, 61 percent were deemed preventable. The more serious the adverse event, the more likely it was to be considered potentially preventable. These rates were approximately four-times higher than had been previously reported [103] but may reflect the better documentation of ADEs at these institutions.

Preventable ADEs were most frequently associated with atypical antipsychotics and warfarin therapy (table 6). Neuropsychiatric events (confusion, oversedation, delirium), hemorrhagic events, and gastrointestinal events were the most frequent types of ADEs in the long-term care facilities studied (table 7). In a 12-month observational study of 490 long-term care residents taking warfarin in 25 nursing homes, there were 720 ADEs (625 minor, 82 serious, and 13 life-threatening); 57 percent of the serious events were considered preventable [104].

Atypical antipsychotics — Atypical antipsychotic medications, used for the management of the behavioral and psychological symptoms of dementia, are among the drugs most frequently associated with adverse events in long-term care facilities [101]. In particular, psychotropic medications are associated with an increased risk for falls. In one meta-analysis of patients age 60 or older, the odds ratio for any psychotropic use among patients who had one or more falls was 1.73 (95% CI 1.52-1.97) [105].

There is limited evidence to support the efficacy of these agents for management of behavioral and psychological symptoms in older adults. (See “Management of neuropsychiatric symptoms of dementia”, section on ‘Antipsychotic drugs’ and “Second-generation antipsychotic medications: Pharmacology, administration, and side effects”.)

Nonetheless, use of antipsychotic medications in long-term care facilities is widespread. A study of 19,780 older adults with no history of major psychosis prior to long-term care admission found that antipsychotic therapy was prescribed for 17 percent within 100 days of their long-term care admission and for 24 percent within one year [106]. A study of 485 nursing homes in Canada found that there was about a threefold variation in antipsychotic prescribing, not related to clinical factors, between high- and low-prescribing facilities [107].

A public health advisory warning issued from the US Food and Drug Administration (FDA) warns of fatal adverse events in demented patients treated with atypical antipsychotic therapy [108-110]. Data from 17 trials of older adult patients with dementia have shown that those treated with atypical antipsychotic therapy were 1.6 to 1.7 times more likely to die than those given placebo therapy. Similar concerns have been raised for haloperidol and other conventional antipsychotics [111,112]. A retrospective comparison of patients with dementia who were newly treated with atypical antipsychotics, compared with no antipsychotics, found an increased risk of death at 30 and 180 days for the treated group (at 30 days, adjusted hazard ratio [HR] 1.55, 95% CI 1.15-2.07) [113]. Mortality was further increased, again by a factor of 1.55, for patients receiving conventional antipsychotics compared with atypical antipsychotics. These data point to the need to rethink the role of these therapies in clinical practice. (See “Management of neuropsychiatric symptoms of dementia”, section on ‘Severe or refractory symptoms’.)

Predicting adverse drug reactions

A tool has been developed to identify older adult patients at increased risk for an adverse drug reaction (ADR) in hospital [114]. The tool, based on logistic regression analysis from a group of Italian patients mean age 78, and validated in a separate European cohort, found that the number of drugs prescribed and prior history of an ADR were the strongest predictors for a subsequent ADR. Compared with those receiving five or fewer medications, the risk of ADR was approximately doubled (odds ratio [OR] 1.9, 95% CI 1.35-2.68) for those prescribed five to seven medications, and was fourfold (OR 4.07, CI 2.93-5.65) for those receiving eight or more medications. Other variables incorporated in this tool are the presence of four or more comorbid conditions, heart failure, liver disease, or renal failure.

Preventing adverse drug events — The occurrence of preventable ADEs is a significant concern. Inappropriate ordering and inadequate monitoring are the most common errors in preventable adverse drug events. Errors in transcription, dispensing, and administration are less commonly identified [101].

Medications that are commonly implicated in preventable ADEs are not generally those identified by widely utilized “bad drug” lists. “Good drugs” prescribed in an inappropriate manner may be far more problematic. When drugs do cause problems, it is often because they are prescribed, dosed, or monitored inappropriately.

Prevention of ADEs in the hospital setting is discussed separately. (See “Prevention of adverse drug events in hospitals”.)

Long-term care — Enhanced surveillance and reporting systems for ADEs occurring in the nursing home setting are needed. Computerized order entry in the hospital setting has been shown to reduce serious medication errors [115]. A computer-based decision aid reduced in-hospital inappropriate dosing of psychotropic medications for geriatric inpatients [116]. However, a randomized trial of computerized order entry with clinical decision support in 29 resident care units at two long-term care facilities in Canada did not affect the rate of ADEs [117].

Community care — Patient errors in medication adherence are a significant contributor to ADEs for older patients living in the community, accounting for 21 percent of preventable ADEs in a large ambulatory Medicare population [118]. Patient errors occurred more frequently in patients who were regularly taking three or more medications, compared with those taking two or fewer [119].

Practical recommendations to reduce medical errors in the community have been proposed [120-125]:

●Maintain an accurate list of all medications that a patient is currently using. This list should include the drug name (generic and brand), dose, frequency, route, and indication.

●Advise periodic “brown-bag check-ups.” Instruct patients to bring all pill bottles to each medical visit; bottles should be checked against the medication list.

●Patients should be made aware of potential drug confusions: sound-alike names, look-alike pills, and combination medications.

●Patients should be informed of both generic and brand names, including spelling, as well as the reasons for taking their medications. This may prevent unnecessary confusion when drugs are inconsistently labeled. As an example, a patient may be unaware that digoxin (generic) and Lanoxin (brand) are the same therapy.

●Medication organizers that are filled by the patient, family member, or caregiver can facilitate compliance with drug regimens. Blister packs for individual drugs, prepared by the pharmacist, can also be helpful in ensuring that patients take their medications correctly [124].

●Community pharmacists are an important resource and can play a key role in working with older adults to reduce medication errors.

Transitions in care settings — Transitions in care, between hospital and nursing home or institutional setting and home, are a common source of medication errors and confusions:

●One Canadian multisite study found that 23 percent of 328 older adults experienced an ADE after discharge home from the hospital; half of these ADEs were considered preventable [120].

●Changes in medication (different dose, discontinued therapies, additional therapies) were identified in 45 of 50 patients discharged from a geriatric ward in the United Kingdom within 6 to 14 days of discharge [121]. Of particular concern is discharge of older patients with new prescriptions for benzodiazepines that were initiated in the hospital, leading to unplanned chronic benzodiazepine use [126].

●Attending clinicians from an academic medical center reported that they believed 89 percent of their discharged patients (n = 99) understood potential side effects of their medications; 58 percent of those discharged patients reported that they understood this information [127].

●ADEs attributed to medication changes occurred in 20 percent of patients on transfer from hospital to a nursing home, occurring most commonly for patients being readmitted to the nursing home (12 of 14 events) [128].

●Frail older people are often found to be on unnecessary drug regimens at the time of hospital discharge. Among 384 older veterans, 44 percent were found to have at least one unnecessary drug therapy at the time of discharge [129]. Factors contributing to this include multiple prescribers, “routine” medications for hospitalization such as antacids or stool softeners, and being on nine or more drug therapies.

Effort must be made to improve communication in “hand-offs” of patient care during transitions in care setting. This is particularly true when the physician responsible for the patient in the hospital is not the same as the physician providing the patient’s longitudinal care. Accurate medication lists, direct communications between providers, and a thorough review of all medications at the time of care transition for appropriateness and intended duration of treatment, are steps that should be taken to avoid ADEs. Whenever possible, the number of prescribing physicians for an individual patient should be limited, as the number of prescribing physicians is an independent risk factor for ADEs [130]. Safe and effective hospital discharge principles are discussed separately. (See “Hospital discharge and readmission”.)

A STEPWISE APPROACH TO PRESCRIBING — Presented below is one systematic approach to improving prescribing practices when managing older adults. Other systematic approaches have been described incorporating similar elements [131]. Regardless of the sequence of steps, what is essential in prescribing is to continually reappraise the patient’s medication regimen in light of his or her current clinical status, goals of care, and the potential risks/benefits of each medication.

A concept of “time to benefit” (TTB) in relation to drug prescribing for older patients with multiple morbidities can be applied to therapeutic decisions [132]. TTB, defined as the time to significant benefit observed in trials of people treated with a drug compared with controls, can be estimated from data from randomized controlled trials. Such information, not routinely available, may in the future help guide decision-making for specific drug prescribing in individual patients.

Review current drug therapy — Periodic evaluation of a patient’s drug regimen is an essential component of medical care for an older person. Such a review may indicate the need for changes to prescribed drug therapy. These changes may include discontinuing a therapy prescribed for an indication that no longer exists, substituting a therapy with a potentially safer agent, changing a drug dose, or adding a new medication (table 8). A medication review should consider whether a change in patient status (eg, renal or liver function) might necessitate dosing adjustment, the potential for drug-drug interaction, whether patient symptoms might reflect a drug side effect, or whether the regimen could be simplified [133]. Medication reviews are often not done in a systematic manner. A reasonable approach could be having a patient meet with a pharmacist within a few weeks of starting a new medication.

In addition to routine review of therapy, review of drug therapy is indicated when patients present with an injury or illness that might have been an adverse result of a prescribed medication. As an example, one study reviewed data for a sample of 168,000 Medicare patients seen for medical care with a fracture of a hip, shoulder, or wrist [134]. In the four months prior to presentation, three-quarters of the patients had been taking a nonopioid drug associated with increased fracture risk (eg, sedative, atypical antipsychotic, or antihypertensive). In the four months after the fracture, such drugs were discontinued for 7 percent but were newly prescribed for another 7 percent.

In a survey of Medicare beneficiaries, more than 30 percent of patients reported they had not talked with their doctor about their different medications in the previous 12 months [135]. Ideally, the clinician should ask the patient to bring to the visit all of the bottles of pills that they are using. Patients may not consider over-the-counter products, ointments, vitamins, ophthalmic preparations, or herbal medicines to be drug therapies and need to be specifically told to bring these to the visit.

Unintended medication discrepancies, particularly likely to occur at the time of hospital admissions, are a common source for medication errors. As an example, one study evaluated 151 patients (average age 77 years) admitted to general internal medicine clinical teaching units and found discrepancies in more than half between admission medication orders and the patient’s usual drug therapies as identified by a medication history interview [136]. Most discrepancies involved unintentional omission of a maintenance medication and more than a third of these discrepancies had the potential to cause moderate harm.

Discontinue unnecessary therapy — Clinicians are often reluctant to stop medications, especially if they did not initiate the treatment and the patient seems to be tolerating the therapy. Sometimes, this exposes the patient to the risks for an adverse event with limited therapeutic benefit. A common example is the use of digoxin in older adults, often prescribed for indications that have not been well-documented. Renal impairment or temporary dehydration may predispose older adults to digoxin toxicity [137]. Although digoxin therapy can be safely discontinued in selected nursing home residents, it is important to recognize that discontinuation in patients with impaired systolic function can have a detrimental effect [138]. (See “Overview of the therapy of heart failure with reduced ejection fraction”.)

The decision to discontinue medication is determined in part by the goals of care for that patient and the risks of adverse effects for that patient. Targets for treatment, based on outcomes evidence from studies in younger patients, may not be appropriate for older adults [30]; thus clinical guidelines not targeted to older patients may foster overly aggressive goals for management of hypertension or diabetes in the older adult population.

One approach to assessing whether a drug is truly necessary for a given patient is presented in an algorithm (algorithm 1) [139]. In a feasibility study performed in a cohort of 70 community-dwelling patients seen for geriatric assessment, implementation of this algorithm led to recommendations to discontinue 58 percent of the medications they had been taking. Eighty-one percent of these medications were discontinued, 2 percent were restarted, and no significant adverse events were attributable to discontinuation over 13-month follow-up.

Some preventive and other therapies may no longer be beneficial to patients with short life expectancies [32]. The appropriateness of these therapies should be reconsidered when other medical conditions develop that impact a patient’s long-term prognosis, unless the therapies are thought to increase comfort.

There are limited studies about how best to withdraw medications [31]. It is reasonable to gradually taper off most medications to minimize withdrawal reactions and to allow symptom monitoring, unless dangerous signs or symptoms indicate a need for abrupt medication withdrawal. Certain common drugs require tapering, including beta blockers, opioids, barbiturates, clonidine, gabapentin, and antidepressants.

Consider adverse drug events for any new symptom — Before adding a new therapy to the patient’s drug regimen, clinicians should carefully consider whether the development of a new medical condition could be the presentation of an atypical ADE to an existing drug therapy. Many prescribing cascade scenarios have been identified (table 5). (See ‘Prescribing cascades’ above.)

Consider nonpharmacologic approaches — Some conditions in older adults may be amenable to lifestyle modification in lieu of pharmacotherapy. The Trial of Nonpharmacologic Interventions in the Elderly (TONE) demonstrated that weight loss and reduced sodium intake could allow discontinuation of antihypertensive medication in about 40 percent of the intervention group [140,141]. (See “Treatment of hypertension in older adults, particularly isolated systolic hypertension”, section on ‘Lifestyle modifications’.)

Care in the use of common drugs — Some commonly prescribed drugs may result in increased toxicity in older adults. As an example, numerous studies have documented adverse events associated with nonsteroidal antiinflammatory drug (NSAID) use, including gastrointestinal bleeding [142], renal impairment [143], and heart failure in this population [144]. NSAIDs should be used cautiously in older adults and generally for a limited duration. (See “Nonselective NSAIDs: Overview of adverse effects”.)

Reduce the dose — Many ADEs are dose-related. When prescribing drug therapies, it is important to use the minimal dose required to obtain clinical benefit. As an example, one study evaluated the relationship between prescribing of the newer atypical antipsychotic therapies (eg, olanzapine, risperidone, and quetiapine) and the development of parkinsonism in older adults [86]. Relative to those dispensed a low dose, those dispensed a high dose were more than twice as likely to develop parkinsonism (HR 2.07, 95% CI 1.42-3.02). As another example, one case-control study in patients over age 70 who received thyroid supplementation identified a correlation between risk of fracture and dose of levothyroxine, indicating the importance of testing for thyroid levels in this population and adjusting the dose accordingly [145].

Simplify the dosing schedule — When multiple medications are required, greater regimen complexity will increase the likelihood of poor compliance or confusion with dosing. Older adults, and particularly those with low health literacy, are not able to efficiently consolidate prescription regimens to optimize a dosing schedule [146]. The Institute of Medicine has proposed a standardized schedule for specifying medication dosing (morning, noon, evening, bedtime), recognizing that 90 percent of prescriptions are taken four or fewer times daily [147].

Simplifying the medication dosing schedule, when possible, is also important in the long-term care setting where nursing staff and time requirements for medication administration are substantial. A study illustrated that within a seven-hour shift, on a 20-bed unit, with two scheduled periods of medication administration, the process of administering medications to the residents accounted for a third of the nursing time [148]. This makes the nurse less available for other important patient care tasks.

Prescribe beneficial therapy — The fewer-the-better approach to drug therapy in older adults is often not the best response to optimizing drug regimens. Avoiding medications with known benefits to minimize the number of drugs prescribed is inappropriate. Patients must be informed about the reason to initiate a new medication and what the expected benefits are.

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

●Basics topics (see “Patient education: Taking medicines when you’re older (The Basics)” and “Patient education: Side effects from medicines (The Basics)”)

SUMMARY AND RECOMMENDATIONS

●The possibility of an adverse drug event (ADE) should always be borne in mind when evaluating an older adult; any new symptom should be considered drug-related until proven otherwise. Pharmacokinetic changes lead to increased plasma drug concentrations and pharmacodynamic changes lead to increased drug sensitivity in older adults. (See ‘Introduction’ above.)

●Clinicians must be alert to the use of herbal and dietary supplements by older patients, who may not volunteer this information and are prone to drug-drug interactions related to these supplements. (See ‘Herbal and dietary supplements’ above.)

●Various criteria sets exist identifying medications that should not be prescribed, or should be prescribed with caution, in older adults. Compliance with these lists of medications to be avoided is suboptimal. (See ‘Inappropriate medications’ above.)

●Clinicians also under-prescribe medications, such as statins, that could provide benefit for older adults. Clinicians may be better at avoiding overprescribing of inappropriate drug therapies than at prescribing indicated drug therapies. Patient financial constraints and unavailability of prescribed doses may contribute to medication underutilization. (See ‘Underutilization of appropriate medication’ above.)

●ADEs result in four times as many hospitalizations in older, compared with younger, adults. Prescribing cascades, drug-drug interactions, and inappropriate drug doses are causes of preventable ADEs. (See ‘Adverse drug events’ above.)

●ADEs are a particular problem for nursing home residents; atypical antipsychotic medications and warfarin are the most common drugs involved in ADEs in this population. (See ‘Adverse drug events in long-term care setting’ above.)

●A stepwise approach to prescribing for older adults should include: periodic review of current drug therapy; discontinuing unnecessary medications; considering nonpharmacologic alternative strategies; considering safer alternative medications; using the lowest possible effective dose; including all necessary beneficial medications. (See ‘A stepwise approach to prescribing’ above.)

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:adverse drug reactions, drugs, Inflammation, medications, Older Adults, overdose, seniors, toxins, USALeave a comment on Drug prescribing for older adults in the USA

Seniors are over medicated in America

via Seniors are over medicated in America

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuLeave a comment on Seniors are over medicated in America

Seniors are over medicated in America

Overmedication and Seniors | Problem of Overmedication

https://www.parentgiving.com/elder-care/overmedication-in-the-elderly/

As we age we are prone to more chronic conditions that require medication. At the same time, an aging body tolerates drugs differently and metabolizes drugs more slowly than it did when we were young, making drug interaction a greater concern. Many seniors mix over the counter drugs and dietary supplements with …

Has overmedicating seniors become ‘America’s other drug problem …

https://www.pbs.org/newshour/health/polypharmacy-americas-drug-problem

Aug 30, 2016 – An increasing number of elderly patients nationwide are on multiple medications to treat chronic diseases, raising their chances of dangerous drug interactions and serious side … A doctor had prescribed blood pressure medication for a 99-year-old woman at a dose that could cause her to faint or fall.

Seniors are given so many drugs, it’s madness – The Globe and Mail

https://www.theglobeandmail.com/opinion/seniors-are…so-many…/article29061583/

Mar 8, 2016 – Two-thirds of Canadians over 65 have five or more different prescriptions, and one-quarter take 10 or more prescription drugs. The older you get, the … The Canadian Deprescribing Network has set the lofty goal of reducing unnecessary and inappropriate medication use in seniors by 50 per cent by 2020.

Is your parent overmedicated? – Health – Health care | NBC News

http://www.nbcnews.com/id/27645077/ns/health-health_care/…/epidemic-overmedication/

Nov 17, 2008 – When Siri Carpenter suspected her mother’s multiple prescriptions were causing memory loss, she discovered an epidemic that affects millions.

Are Seniors Being Overmedicated? – MedShadow

https://medshadow.org/features/are-seniors-being-overmedicated/

Sep 17, 2015 – How many medicines do you take? It’s a question that stumps many seniors and people with chronic illnesses. That’s because more people today take 5, 6 or more medicines simultaneously — and they take some of those drugs for years. Doctors call this polypharmacy. For some people it’s essential to …

Is the Nursing Home Over-Medicating Your Elderly Parent? – Aging Care

https://www.agingcare.com/…/overmedicating-elderly-in-nursing-homes-138448.htm

In the days before nursing homes were under so much regulation, many homes used heavy medicationto “manage” residents. Elders who slept most of the day, as well as all night, didn’t require as much staff time. Therefore, many homes considered drugging people efficient and cost containing. Anti-psychotics were …

Old And Overmedicated: The Real Drug Problem In Nursing Homes …

https://www.npr.org/…/old-and-overmedicated-the-real-drug-problem-in-nursing-homes

Dec 8, 2014 – Way too many residents of U.S. nursing homes are on antipsychotic drugs, critics say. It’s often just for the convenience of the staff, to sedate patients agitated by dementia. That’s illegal.

New Study Highlights Dangers of Over-Medicated Seniors – ABC News

abcnews.go.com/Health/study-highlights-dangers-medicated-seniors/story?id…

Aug 23, 2012 – Polypharmia. That’s the shorthand used to describe older patients who take more drugs than they actually need. Now a new study shows just how much of a problem this really is.

Are senior citizens being overmedicated? – The Chart – CNN.com Blogs

thechart.blogs.cnn.com/2011/06/03/are-senior-citizens-being-overmedicated/

Jun 3, 2011 – … care during the final years of their lives. Laura Steckler, a Florida resident, recently sought treatment for her elderly mother after she suffered an episode of paranoia and hallucinations. She tells CNN how she found herself in the middle of the debate over how much is too much medicationfor the elderly: …

Overmedication Of The Elderly Is A National Disgrace | HuffPost

https://www.huffingtonpost.com/…/overmedication-of-the-elderly_b_1354215.html

Mar 23, 2012 – In 1982, I formed the Foundation Aiding The Elderly (FATE) after my beloved aunt wasovermedicated by her family physician and subsequently fell, broke her hip and ended up in a nursing home for rehabilitation. My aunt entered this nursing home for rehabilitation; however, she never received the …

—————-

Connie’s comments: I have been a caregiver for many seniors in the bay area and 90% of them are over medicated. They rely on their family members and care providers to tell their doctors to review their medications or to lower their dosage.

logo

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:over medicated, seniors2 Comments on Seniors are over medicated in America

Let America Vote

Let America Vote Logo
A whopping 10 percent of people in Florida can’t vote because of the state’s strict felon disenfranchisement law. Florida strips more people with felony convictions of their right to vote than any other state.
But, there’s good news: The team working to get this measure on the ballot in 2018 just passed their signature threshold! Florida will decide this November if over 1.6 million previously disenfranchised people can have the right to vote.
If you’ve paid your debt to society, you should get back the right to vote. It’s that simple. Sign our petition if you support restoring voting rights to people with felony convictions in Florida.
Florida’s disenfranchisement of people with felony convictions dates back to 1868 during the Jim Crow era.
Nearly 1 in 5 African American adults remain disenfranchised because of a criminal record.
If passed, this initiative would automatically restore the rights of Floridians who have served their time for a felony conviction.
Floridians who have felony convictions are one step closer to having their voting rights restored. Add your name if you want to see access to the ballot box expanded to 1.6 million people in Florida.
As Jason says, “If you’ve done your time, you should get to vote.” Let’s make sure people in Florida who have served their time get the opportunity to be full citizens and vote again.
Thanks,
Leigh Chapman
Senior Policy Advisor, Let America Vote
Posted byconnie dello buonoJanuary 24, 2018Posted inPoliticsLeave a comment on Let America Vote

Is Obesity ‘Contagious’?

Is Obesity ‘Contagious’?

News Picture: Is Obesity 'Contagious'?By Alan Mozes
HealthDay Reporter

Latest Diet & Weight Management News

  • You’ve Lost the Weight. When Will It Come Back?
  • Why Evenings May Be a Dangerous Time for Dieters
  • Health Tip: Prevent Weight Gain
  • Is Obesity Slowing Gains in U.S. Life Spans?
  • Sleep Better, Lose Weight?
  • Want More News? Sign Up for MedicineNet Newsletters!

TUESDAY, Jan. 23, 2018 (HealthDay News) — Living in a neighborhood with a high rate of obesity might raise the odds that you and your children will become plus-sized, too.

That’s according to a new study involving more than 1,500 U.S. Army families. The researchers say their findings may help explain why high obesity rates in the United States tend to cluster in certain geographic areas.

“Living in a community where obesity is more of the norm than not can influence what is socially acceptable in terms of eating and exercise behaviors and body size,” explained study author Ashlesha Datar.

A phenomenon called “social contagion” may be at work, she said, though the study did not prove a cause-and-effect link.

The bottom line: “If more people around you are obese then that may increase your own chances of becoming obese,” said Datar, a senior economist at the University of Southern California Center for Economic and Social Research.

Datar and co-author Nancy Nicosia, of the RAND Corp., focused on Army families because they typically relocate based on military requirements rather than personal preference. This eliminated from the get-go one theory about regional obesity — that people who are obese associate with others like themselves.

The researchers sifted through 2013-2014 data for about 1,300 parents and 1,100 children. The families were stationed at or near 38 military installations across the United States.

Datar wanted to see if families had higher odds for being overweight or obese when posted in counties with higher rates of obesity.

The team first reviewed body mass index (BMI) for family members. BMI is a measure of body fat based on height and weight.

They then assessed the “shared environment” in which service families lived, tallying up the number of grocery stores, sports and recreational facilities, and such.

The researchers also weighed each community’s overall obesity rate. These ranged from 21 percent (El Paso County, Colo.) to 38 percent (Vernon County, La.).

Datar said the analysis confirmed that “military families assigned to installations in counties with higher obesity rates were more likely to be overweight or obese than military families assigned to installations in counties with lower rates of obesity.”

But the opposite also appears true: Relocating to a county with a lower obesity rate reduces a family’s odds of plumping up.

Datar said the study found no evidence to suggest that “neighborhood shared environments” — such as access to the same eating and exercise options — were driving obesity rates.

Lona Sandon is an assistant professor of clinical nutrition at the University of Texas Southwestern Medical Center at Dallas.

“It is well known in the behavior and psychology literature that those around us influence behaviors, values and beliefs,” she said.

“That includes behaviors, values and beliefs related to health, eating and exercise,” Sandon added. “Social acceptability and norms have a lot to do with food and exercise behavior choices, whether we are aware of it or not.”

Her own research suggests “most people believed they were in control of their behaviors,” said Sandon, who wasn’t involved in the study.

But when asked about specific situations — like eating out with friends and whether what their friends ordered influenced their choice of meal — the respondents’ answers changed. “They would often realize that others around them did influence meal choices,” she said.

Sandon’s advice: “If you want to change your weight, eating and exercise habits, get new friends who are already eating healthier and exercising.”

The findings were published online in the Jan. 22 issue of the Journal of the American Medical Association.

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:obesityLeave a comment on Is Obesity ‘Contagious’?

Factors that increase your risk for a secondary cancer

Factors that increase your risk for a secondary cancer

secondary cancer

Several factors can make you more likely to develop a secondary cancer. Some are under your control. Others aren’t. It’s important for you to discuss your risks with your doctor and find out what you can do to lower your odds of developing cancer again. Equally important, discuss how often you need to get screened, so you can catch any new cancers early.

Childhood cancer. If you developed cancer before age 15, you’ll need to stay on top of your health in the years to come. Some childhood tumors are caused by inherited syndromes that contribute to a lifelong increased risk for cancer. For example, Li-Fraumeni syndrome can lead to sarcoma, leukemia, and brain and breast cancers. The treatments you received to combat childhood cancer can also make you more vulnerable to future malignancies.

Family history. When you have multiple close relatives who all developed a particular cancer, that’s a very strong indication that your family carries a genetic susceptibility. Though you can’t change your genes, you can get tested for genetic changes that are associated with increased cancer risk and—if you are at higher risk—be screened for those cancers and take other preventive measures.

Cancer treatment. Radiation, chemotherapy, and other cancer therapies, while necessary to cure your disease, can also trigger cellular changes that make you more vulnerable to a secondary cancer. Your doctor will make every possible effort to structure your initial treatment—for example, fine-tuning the drug and dose—to destroy the cancer, while minimizing your future cancer risks.

Age. The older you are, the higher your cancer risk. Each passing year brings more chronic conditions, more exposure to environmental factors that increase your risk, and a lower ability of cells to repair damage.

Lifestyle. Lifestyle is one cancer risk you can control. Many of the choices you make each day can influence—sometimes significantly—your chances of getting a future cancer. Here are a few things you can do to reduce your risks:

  • Eat a nutritious diet that’s heavy in cancer-fighting foods, like broccoli and other cruciferous vegetables, dark leafy greens, beans and peas, berries, cherries, tomatoes, and nuts.
  • Exercise for at least 30 minutes a day, five days a week.
  • Keep your body mass index (BMI) within a healthy range.
  • If you smoke, ask your doctor for help quitting. Also avoid secondhand smoke.
  • Limit alcohol intake to no more than one 6-ounce glass of wine (or the equivalent) a day for women and one or two glasses for men.
  • Wear UVA/UVB–protective sunscreen whenever you go outside.

To learn more about cancer and its effects on the mind and body, buy Life After Cancer, a Special Health Report from Harvard Medical School.


Connie’s comments: Avoid or lessen exposure to environmental toxins.

Posted byconnie dello buonoJanuary 24, 2018Posted inMenuTags:cancerLeave a comment on Factors that increase your risk for a secondary cancer

Posts pagination

Newer posts 1 … 143 144 145 146 147 … 850 Older posts
image 30

Contact to request for caregiver, free senior safe your home consult, free assessment of home care needs, free tips on caring for your parents at home, avoid emergencies, have consistent home care and more.

Reach Us

  • +14088541883
  • +4088541883
  • motherhealth@gmail.com
  • 1273 Sandia Ave Sunnyvale CA 94089

Company

  • Caregivers
  • Senior
  • Blogs
  • About Us
  • Contact Us
  • Marketplace
  • Book an Appointment
  • Caregivers
  • Senior
  • Blogs
  • About Us
  • Contact Us
  • Marketplace
  • Book an Appointment

Follow Us

Facebook Linkedin Twitter

Copyright © 2026 KRM Digital Solutions

 

Loading Comments...